Baidu
map

J Ethnopharmacol:五味子提取物能降低环磷酰胺导致的大鼠肝脏、肾脏和脑部毒性

2017-08-21 MedSci MedSci原创

五味子,Schisandra chinensis(Turcz.)Baill(S. chinensis)已经在中国被使用了几千年,常用于治疗尿路疾病和肝损伤。五味子,酸、甘,温。具有收敛固涩,益气生津,补肾宁心,兴奋中枢神经系统,改善人的智力活动,促进肝糖原异生,保肝解毒,抗菌抗病毒等作用。用于久嗽虚喘,梦遗滑精,遗尿、尿频,久泻不止,自汗、盗汗,津伤口渴,短气脉虚,内热消渴,心悸失眠。既往的研究已

五味子,Schisandra chinensis(Turcz.)Baill(S. chinensis)已经在中国被使用了几千年,常用于治疗尿路疾病和肝损伤。五味子,酸、甘,温。具有收敛固涩,益气生津,补肾宁心,兴奋中枢神经系统,改善人的智力活动,促进肝糖原异生,保肝解毒,抗菌抗病毒等作用。用于久嗽虚喘,梦遗滑精,遗尿、尿频,久泻不止,自汗、盗汗,津伤口渴,短气脉虚,内热消渴,心悸失眠。

既往的研究已经发现五味子提取物(S. chinensis extract,SCE)对肝脏、肾脏和神经系统具有保护作用,而五味子木脂素是SCE的活性成分。为了探讨SCE和环磷酰胺(CTX)之间的药代动力学方面的中草药-药物相互作用(HDIs),及评价SCE对CTX所致的大鼠肝损伤、肾损伤和脑损伤的保护作用,来自上海第二军医大学的研究人员设计并完成了该研究,并将研究结果在线发表在8月中旬的《民族药理学》杂志上。研究的主要内容如下:

研究人员使用UPLC-MS/MS方法测定了CTX和三种代谢产物(4-酮基环磷酰胺[4-Keto]、2-脱氯乙基环磷酰胺[DCCTX] 和羧基磷酰胺[CPM])的血浆浓度,进而研究SCE和CTX的药代动力学方面的HDIs。为了评估SCE预处理的保护作用,研究人员还对大鼠肝、肾和脑组织进行了毒性和氧化应激评估,以及组织学研究。

研究人员发现,代谢产物DCCTX的产生能等摩尔地反映大鼠中氯乙醛(CAA,CTX的有毒代谢产物中的一种)的产生。SCE能显著降低CAA的产生,以及降低DCCTX的Cmax和AUC0-24h,分别降低了69%和49%(P<0.05)。与只使用CTX组相比,经过连续7天的SCE预处理后,DCCTX的Cmax和AUC0-24h仍降低了(降低了25%和37%,P<0.05)。平行毒性和氧化应激研究表明,单剂量SCE预处理可显著降低血浆BUN和Cr水平(分别降低了12%和46%),同时也能降低肝天冬氨酸转氨酶(AST)的活性(降低了32%)。此外,SCE预处理能有效增加脑组织中谷胱甘肽(GSH)的含量(约增加了7.8倍),以及降低丙二醛(MDA)水平(在大鼠肝、肾和脑组织中分别降低了39%、28%和31%)。组织学研究也支持SCE的保护作用。

该研究的结果表明,在CTX治疗中,五味子可作为一种补充疗法。

原始出处:

Zhai J, Zhang F,et al.Schisandra chinensis extract decreases chloroacetaldehyde production in rats and attenuates cyclophosphamide toxicity in liver, kidney and brain.J Ethnopharmacol. 2017 Aug 15. pii: S0378-8741(17)30821-8. doi: 10.1016/j.jep.2017.08.020. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1908304, encodeId=2c1f1908304fc, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Feb 20 01:06:00 CST 2018, time=2018-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996036, encodeId=c7901996036d5, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 03 12:06:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787308, encodeId=e7131e8730887, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Sep 23 07:06:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788239, encodeId=2adc1e8823965, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Oct 09 08:06:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236991, encodeId=e61723699189, content=谢谢分享谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Aug 25 13:58:21 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284354, encodeId=152b128435494, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68524, encryptionId=73216852458, topicName=环磷酰胺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Wed Aug 23 12:06:00 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236123, encodeId=0616236123fd, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Tue Aug 22 22:39:02 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235950, encodeId=e890235950c1, content=该研究的结果表明.在CTX治疗中.五味子可作为一种补充疗法. , beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Tue Aug 22 08:25:54 CST 2017, time=2017-08-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1908304, encodeId=2c1f1908304fc, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Feb 20 01:06:00 CST 2018, time=2018-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996036, encodeId=c7901996036d5, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 03 12:06:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787308, encodeId=e7131e8730887, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Sep 23 07:06:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788239, encodeId=2adc1e8823965, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Oct 09 08:06:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236991, encodeId=e61723699189, content=谢谢分享谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Aug 25 13:58:21 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284354, encodeId=152b128435494, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68524, encryptionId=73216852458, topicName=环磷酰胺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Wed Aug 23 12:06:00 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236123, encodeId=0616236123fd, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Tue Aug 22 22:39:02 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235950, encodeId=e890235950c1, content=该研究的结果表明.在CTX治疗中.五味子可作为一种补充疗法. , beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Tue Aug 22 08:25:54 CST 2017, time=2017-08-22, status=1, ipAttribution=)]
    2017-10-03 yb6560
  3. [GetPortalCommentsPageByObjectIdResponse(id=1908304, encodeId=2c1f1908304fc, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Feb 20 01:06:00 CST 2018, time=2018-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996036, encodeId=c7901996036d5, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 03 12:06:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787308, encodeId=e7131e8730887, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Sep 23 07:06:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788239, encodeId=2adc1e8823965, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Oct 09 08:06:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236991, encodeId=e61723699189, content=谢谢分享谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Aug 25 13:58:21 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284354, encodeId=152b128435494, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68524, encryptionId=73216852458, topicName=环磷酰胺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Wed Aug 23 12:06:00 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236123, encodeId=0616236123fd, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Tue Aug 22 22:39:02 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235950, encodeId=e890235950c1, content=该研究的结果表明.在CTX治疗中.五味子可作为一种补充疗法. , beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Tue Aug 22 08:25:54 CST 2017, time=2017-08-22, status=1, ipAttribution=)]
    2017-09-23 jj000001
  4. [GetPortalCommentsPageByObjectIdResponse(id=1908304, encodeId=2c1f1908304fc, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Feb 20 01:06:00 CST 2018, time=2018-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996036, encodeId=c7901996036d5, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 03 12:06:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787308, encodeId=e7131e8730887, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Sep 23 07:06:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788239, encodeId=2adc1e8823965, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Oct 09 08:06:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236991, encodeId=e61723699189, content=谢谢分享谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Aug 25 13:58:21 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284354, encodeId=152b128435494, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68524, encryptionId=73216852458, topicName=环磷酰胺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Wed Aug 23 12:06:00 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236123, encodeId=0616236123fd, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Tue Aug 22 22:39:02 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235950, encodeId=e890235950c1, content=该研究的结果表明.在CTX治疗中.五味子可作为一种补充疗法. , beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Tue Aug 22 08:25:54 CST 2017, time=2017-08-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1908304, encodeId=2c1f1908304fc, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Feb 20 01:06:00 CST 2018, time=2018-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996036, encodeId=c7901996036d5, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 03 12:06:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787308, encodeId=e7131e8730887, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Sep 23 07:06:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788239, encodeId=2adc1e8823965, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Oct 09 08:06:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236991, encodeId=e61723699189, content=谢谢分享谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Aug 25 13:58:21 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284354, encodeId=152b128435494, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68524, encryptionId=73216852458, topicName=环磷酰胺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Wed Aug 23 12:06:00 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236123, encodeId=0616236123fd, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Tue Aug 22 22:39:02 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235950, encodeId=e890235950c1, content=该研究的结果表明.在CTX治疗中.五味子可作为一种补充疗法. , beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Tue Aug 22 08:25:54 CST 2017, time=2017-08-22, status=1, ipAttribution=)]
    2017-08-25 明天会更好!

    谢谢分享谢谢分享!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1908304, encodeId=2c1f1908304fc, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Feb 20 01:06:00 CST 2018, time=2018-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996036, encodeId=c7901996036d5, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 03 12:06:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787308, encodeId=e7131e8730887, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Sep 23 07:06:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788239, encodeId=2adc1e8823965, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Oct 09 08:06:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236991, encodeId=e61723699189, content=谢谢分享谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Aug 25 13:58:21 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284354, encodeId=152b128435494, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68524, encryptionId=73216852458, topicName=环磷酰胺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Wed Aug 23 12:06:00 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236123, encodeId=0616236123fd, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Tue Aug 22 22:39:02 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235950, encodeId=e890235950c1, content=该研究的结果表明.在CTX治疗中.五味子可作为一种补充疗法. , beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Tue Aug 22 08:25:54 CST 2017, time=2017-08-22, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1908304, encodeId=2c1f1908304fc, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Feb 20 01:06:00 CST 2018, time=2018-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996036, encodeId=c7901996036d5, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 03 12:06:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787308, encodeId=e7131e8730887, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Sep 23 07:06:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788239, encodeId=2adc1e8823965, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Oct 09 08:06:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236991, encodeId=e61723699189, content=谢谢分享谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Aug 25 13:58:21 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284354, encodeId=152b128435494, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68524, encryptionId=73216852458, topicName=环磷酰胺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Wed Aug 23 12:06:00 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236123, encodeId=0616236123fd, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Tue Aug 22 22:39:02 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235950, encodeId=e890235950c1, content=该研究的结果表明.在CTX治疗中.五味子可作为一种补充疗法. , beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Tue Aug 22 08:25:54 CST 2017, time=2017-08-22, status=1, ipAttribution=)]
    2017-08-22 thlabcde

    好东西学习了!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1908304, encodeId=2c1f1908304fc, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Feb 20 01:06:00 CST 2018, time=2018-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996036, encodeId=c7901996036d5, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 03 12:06:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787308, encodeId=e7131e8730887, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Sep 23 07:06:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788239, encodeId=2adc1e8823965, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Oct 09 08:06:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236991, encodeId=e61723699189, content=谢谢分享谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Aug 25 13:58:21 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284354, encodeId=152b128435494, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68524, encryptionId=73216852458, topicName=环磷酰胺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Wed Aug 23 12:06:00 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236123, encodeId=0616236123fd, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Tue Aug 22 22:39:02 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235950, encodeId=e890235950c1, content=该研究的结果表明.在CTX治疗中.五味子可作为一种补充疗法. , beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Tue Aug 22 08:25:54 CST 2017, time=2017-08-22, status=1, ipAttribution=)]
    2017-08-22 Julie W

    该研究的结果表明.在CTX治疗中.五味子可作为一种补充疗法.

    0

相关资讯

J Ethnopharmacol:五味子属植物或可治疗神经系统疾病

近日,中科院昆明植物研究所罗怀容和孙汉董研究组合作发现,五味子属三萜类化合物的神经药理活性,可促进脑源性神经营养因子的表达,为该化合物的生物活性研究提供了新思路。研究成果在线发表于《民族药理学》(Journal of Ethnopharmacology)杂志。 五味子属植物除含有丰富的木脂素类化合物外,还含有结构多样的三萜类化合物,如尼哥纳乐酸等,但在神经药理学上却几乎没有研究报道。 钙离子作

Baidu
map
Baidu
map
Baidu
map